Promomed developed injectable form of Areplivir for hospitalized patients with COVID-19
Promomed 28 April 2021
Promomed Group starts clinical trials of injectable form of Areplivir for the treatment of coronavirus infection. The Ministry of Health of the Russian Federation has issued a permit to conduct phase I clinical trials.
The safety study of the drug in the form of lyophilizate for solution for infusion will be held at the public healthcare institution Clinical Hospital No. 3 in Yaroslavl and will last until the end of September 2021.
After completing all stages of clinical trials, Russian doctors will receive an effective drug for the treatment of hospitalized COVID-19 patients, including those with a severe course of the disease. Petr Bely, Chairman of the Board of Directors of Promomed Group, said: «We continue scientific developments in the field of creating innovative effective and safe medicines to fight infections. At the same time, we are expanding and modernizing the capacities of the Biokhimik plant in order to provide vital medicines for Russian healthcare in a sustainable manner and with guaranteed quality, including those aimed at treating the new COVID-19 coronavirus infection.»
The safety study of the drug in the form of lyophilizate for solution for infusion will be held at the public healthcare institution Clinical Hospital No. 3 in Yaroslavl and will last until the end of September 2021.
After completing all stages of clinical trials, Russian doctors will receive an effective drug for the treatment of hospitalized COVID-19 patients, including those with a severe course of the disease. Petr Bely, Chairman of the Board of Directors of Promomed Group, said: «We continue scientific developments in the field of creating innovative effective and safe medicines to fight infections. At the same time, we are expanding and modernizing the capacities of the Biokhimik plant in order to provide vital medicines for Russian healthcare in a sustainable manner and with guaranteed quality, including those aimed at treating the new COVID-19 coronavirus infection.»
Today Areplivir (INN: favipiravir) is available in tablets of 40 tablets per package. According to Dmitry Pushkar, academician of the Russian Academy of Sciences and member of the consortium of academic community for the study of coronavirus infection, etiotropic therapy plays important role in COVID-19 therapy. «Favipiravir is recommended by the Ministry of Health of the Russian Federation for the treatment of coronavirus infection of any severity. Data are emerging globally on the effectiveness of combined use of favipiravir and monoclonal antibodies. For hospitalized patients, who most often have severe form of disease, injectable dosage form of favipiravir, on the one hand, will be more convenient in use, on the other hand, it may increase the effectiveness of therapy,» said Dmitry Pushkar.
Areplivir is a drug with targeted action against RNA-containing viruses, which include SARS-CoV-2. In the course of clinical studies conducted in 2020 under the guidance of full members of the Russian Academy of Sciences in 5 medical institutions in Russia, it demonstrated high efficacy in the treatment of a new coronavirus infection (ensuring the elimination of the virus from the body, improving lung condition, reducing the risks of progression to severe stage, and accelerating recovery).
The drug is included in the priority treatment regimen in the guidelines for the treatment of COVID-19 approved by the Ministry of Health. It is included in the list of vital and essential medicines.
Areplivir is a drug with targeted action against RNA-containing viruses, which include SARS-CoV-2. In the course of clinical studies conducted in 2020 under the guidance of full members of the Russian Academy of Sciences in 5 medical institutions in Russia, it demonstrated high efficacy in the treatment of a new coronavirus infection (ensuring the elimination of the virus from the body, improving lung condition, reducing the risks of progression to severe stage, and accelerating recovery).
The drug is included in the priority treatment regimen in the guidelines for the treatment of COVID-19 approved by the Ministry of Health. It is included in the list of vital and essential medicines.
